!

COVID-19 Response 

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Storm Watch

Baylor’s Emergency Response Team is carefully monitoring the progress of tropical storm Beta. The College plans to be open under normal business operations on Monday. View message. 

Baylor College of Medicine

Study on Gene Therapy for Subjects with Severe Sickle Cell Disease (Bluebird HGB-210) (H-44293)

Description

Content

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

AGE REQUIREMENTS: 2 Years to 50 Years  

More information about this study can be found on clinicaltrials.gov at the following linkhttps://clinicaltrials.gov/ct2/show/NCT04293185?cond=NCT04293185&draw=2&rank=1

 NCT#/ClinicalTrials.gov ID: NCT04293185

Contact

Marlen Dinu

Phone 1: 832–824–4881

IRB: H-44293

Status:

Active

Created:

Back to topback-to-top